A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis.
Niyonsaba. François F; Iwabuchi. Kazuhisa K; Someya. Akimasa A; Hirata. Michimasa M; Matsuda. Hiroshi H; Ogawa. Hideoki H; Nagaoka. Isao I
Key Findings
- LL-37 is a strong, dose‑dependent chemotactic factor for mast cells, with an optimal concentration around 5 µg/mL.
- Mast cells have at least two types of LL-37 receptors (high‑ and low‑affinity) that are different from the FPRL1 receptor used by neutrophils and monocytes.
- The chemotactic response relies on Gi protein and phospholipase C signaling, as shown by inhibition with pertussis toxin and a PLC inhibitor.
Practical Outcomes
- For biohackers, this study suggests LL-37 could be explored as an immune‑modulating tool, but it provides no dosage guidelines or safety data for human use. Until more applied research is done, the finding is mainly of scientific interest rather than a ready‑to‑use protocol for longevity or performance enhancement.
Summary
The human antibacterial peptide LL-37 can pull mast cells toward it, acting like a chemical signal that guides these immune cells to sites of inflammation. This effect peaks at about 5 µg/mL and works through a specific signaling pathway, but it doesn't use the same receptor that LL-37 uses in other immune cells.
Abstract
The mast cell is one of the major effector cells in inflammatory reactions and can be found in most tissues throughout the body. During inflammation, an increase in the number of mast cells in the local milieu occurs, and such accumulation requires directed migration of this cell population. As it has previously been reported that the human cathelicidin-derived antibacterial peptide, LL-37, stimulates the degranulation of mast cells, we hypothesized that LL-37 could be a mast cell chemotaxin. The present study shows that LL-37 is a potent chemotactic factor for mast cells. The chemotactic response was dose-dependent and bell-shaped, reaching an optimal concentration of 5 microg/ml. In addition, checkerboard analysis showed that cell migration towards this peptide was chemotactic rather than chemokinetic. Moreover, Scatchard analysis using 125I-labelled LL-37-derived peptide revealed that LL-37 has at least two classes of receptors, namely high- and low-affinity receptors, on mast cells. Furthermore, the competitive binding assay suggested that LL-37 is unlikely to utilize formyl peptide receptor-like 1 (FPRL1), a functional LL-37 receptor for neutrophil and monocyte migration, on mast cells. In addition, the treatment of cells with pertussis toxin and phospholipase C inhibitor, U-73122, inhibited LL-37-mediated migration, indicating that LL-37 induces mast cell chemotaxis through a Gi protein-phospholipase C signalling pathway. These results show that besides its antibacterial activities, LL-37 may have the potential to recruit mast cells to inflammation foci.
Study Information
pubmed
2002
2002-05-01T00:00:00.000Z
10.1046/j.1365-2567.2002.01398.x
451
28